Silvia López-Calvo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Silvia López-Calvo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adela López de Cerain
MITOX Research Group, Department of Pharmaceutical Sciences, Faculty of Pharmacy and Nutrition, UNAV-University of Navarra, Pamplona, Spain
1 shared publication - Ariane Vettorazzi
UNAV - Universidad de Navarra, Departamento de Ciencias Farmacéuticas, MITOX group, Irunlarrea 1, 31008, Pamplona, Navarra, Spain
1 shared publication - Barbara De Santis
Department of Food Safety, Nutrition and Veterinary Public Health, Chemical Food Safety Unit, Italian National Institute of Health, Rome, Italy
1 shared publication - Beatriz Arce-López
Department of Pharmaceutical Technology and Chemistry, Research group MITOX, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Elena González-Peñas
Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Elena Lizarraga
Department of Pharmaceutical Technology and Chemistry, Research group MITOX, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication
Latest Publications
- Open Access
Biomonitoring of Mycotoxins in Plasma of Patients with Alzheimer’s and Parkinson’s Disease
Exposure to environmental contaminants might play an important role in neurodegenerative disease pathogenesis, such as Parkinson´s disease (PD) and Alzheimer´s disease (AD). For the first time in Spain, the plasmatic levels of 19 mycotoxins from patients diagnosed with a neurodegenerative disease (44 PD and 24 AD) and from their healthy companions (25) from La Rioja region were analyzed. The studied mycotoxins were aflatoxins B1, B2, G1, G2 and M1, T-2 and HT-2, ochratoxins A (OTA) and B (OTB), zearalenone, sterigmatocystin (STER), nivalenol, deoxynivalenol, 3-acetyldeoxynivalenol, 15-acetyldeoxynivalenol, deepoxy-deoxynivalenol, neosolaniol, diacetoxyscirpenol and fusarenon-X. Samples were analyzed by LC-MS/MS before and after treatment with β-glucuronidase/arylsulfatase in order to detect potential metabolites. Only OTA, OTB and STER were detected in the samples. OTA was present before (77% of the samples) and after (89%) the enzymatic treatment, while OTB was only detectable before (13%). Statistically significant differences in OTA between healthy companions and patients were observed but the observed differences might seem more related to gender (OTA levels higher in men, p-value = 0.0014) than the disease itself. STER appeared only after enzymatic treatment (88%). Statistical analysis on STER, showed distributions always different between healthy controls and patients (patients’ group > controls, p-value < 0.0001). Surprisingly, STER levels weakly correlated positively with age in women (rho = 0.3384), while OTA correlation showed a decrease of levels with age especially in the men with PD (rho = −0.4643).
Open AccessBiomonitoring of Mycotoxins in Plasma of Patients with Alzheimer’s and Parkinson’s Disease
Exposure to environmental contaminants might play an important role in neurodegenerative disease pathogenesis, such as Parkinson´s disease (PD) and Alzheimer´s disease (AD). For the first time in Spain, the plasmatic levels of 19 mycotoxins from patients diagnosed with a neurodegenerative disease (44 PD and 24 AD) and from their healthy companions (25) from La Rioja region were analyzed. The studied mycotoxins were aflatoxins B1, B2, G1, G2 and M1, T-2 and HT-2, ochratoxins A (OTA) and B (OTB), zearalenone, sterigmatocystin (STER), nivalenol, deoxynivalenol, 3-acetyldeoxynivalenol, 15-acetyldeoxynivalenol, deepoxy-deoxynivalenol, neosolaniol, diacetoxyscirpenol and fusarenon-X. Samples were analyzed by LC-MS/MS before and after treatment with β-glucuronidase/arylsulfatase in order to detect potential metabolites. Only OTA, OTB and STER were detected in the samples. OTA was present before (77% of the samples) and after (89%) the enzymatic treatment, while OTB was only detectable before (13%). Statistically significant differences in OTA between healthy companions and patients were observed but the observed differences might seem more related to gender (OTA levels higher in men, p-value = 0.0014) than the disease itself. STER appeared only after enzymatic treatment (88%). Statistical analysis on STER, showed distributions always different between healthy controls and patients (patients’ group > controls, p-value < 0.0001). Surprisingly, STER levels weakly correlated positively with age in women (rho = 0.3384), while OTA correlation showed a decrease of levels with age especially in the men with PD (rho = −0.4643).